脓毒症后慢性危重症患者持续免疫抑制的证据
这项前瞻性观察研究纳入88例脓毒症危重患者和20名健康对照,按临床轨迹分为早期死亡、快速恢复(RAP)和慢性危重症(CCI)。CCI患者继发感染发生率及按住院时间调整后的总感染数高于RAP患者。脓毒症诊断时患者淋巴细胞绝对计数和单核细胞HLA-DR表达较健康对照显著降低,血浆可溶性PD-L1显著升高,但RAP与CCI之间在诊断时及诊断后24小时内无差异。CCI患者后续未能恢复淋巴细胞绝对计数、HLA-DR和可溶性PD-L1至正常值,而RAP组有恢复趋势。
要点
- 88例脓毒症患者中40%(35例)进展为慢性危重症(CCI),57%(50例)快速恢复(RAP),3%(3例)14天内死亡。
- CCI患者继发感染发生率及按住院时间调整后的总感染数高于RAP患者。
- 脓毒症诊断时淋巴细胞绝对计数和单核细胞HLA-DR表达较健康对照显著降低,血浆可溶性PD-L1显著升高。
- 诊断时及诊断后24小时内,RAP与CCI患者的淋巴细胞绝对计数、可溶性PD-L1和HLA-DR无差异。
- CCI患者后续淋巴细胞绝对计数、HLA-DR和可溶性PD-L1无恢复至正常的趋势,RAP组则有恢复趋势。
适用人群与场景
- 88例脓毒症危重患者和20名健康对照,按临床轨迹分为早期死亡、快速恢复(RAP)和慢性危重症(CCI)。
研究设计与关键结果
- 前瞻性观察研究纳入88例脓毒症危重患者和20名健康对照,按临床轨迹分组。
- 88例中3例(3%)于脓毒症发病14天内死亡,50例(57%)快速恢复,35例(40%)发展为慢性危重症。
- 与快速恢复患者相比,慢性危重症患者继发感染发生率及按住院时间调整后的总感染数更高。
- 脓毒症诊断时淋巴细胞绝对计数和单核细胞HLA-DR表达较健康对照显著降低,血浆可溶性PD-L1显著升高。
- 快速恢复与慢性危重症患者在诊断时及诊断后24小时内淋巴细胞绝对计数、可溶性PD-L1和HLA-DR无差异。
- 慢性危重症患者未出现淋巴细胞绝对计数、HLA-DR和可溶性PD-L1恢复至正常的趋势,快速恢复组则有恢复趋势。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为脓毒症患者在诊断时即存在临床和生物学免疫抑制证据。
- 作者认为进展为慢性危重症者继发感染发生率更高且宿主免疫受损标志物持续异常,但发病时标志物不能区分快速恢复与慢性危重症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Many sepsis survivors develop chronic critical illness (CCI) and are assumed to be immunosuppressed, but there is limited clinical evidence to support this. We sought to determine whether the incidence of secondary infections and immunosuppressive biomarker profiles of patients with CCI differ from those with rapid recovery (RAP) after sepsis.
METHODS: This prospective observational study evaluated 88 critically ill patients with sepsis and 20 healthy controls. Cohorts were defined based on clinical trajectory (early death, RAP, or CCI), whereas immunosuppression was clinically determined by the presence of a postsepsis secondary infection. Serial blood samples were collected for absolute lymphocyte counts (ALCs), monocytic human leukocyte antigen-DR (mHLA-DR) expression, and plasma-soluble programmed death-ligand 1 (sPD-L1) concentrations.
RESULTS: Of the 88 patients with sepsis, 3 (3%) died within 14 days of sepsis onset, 50 (57%) experienced RAP, and 35 (40%) developed CCI. Compared with RAP patients, CCI patients exhibited a higher incidence and overall number of infections adjusted for hospital length of stay. ALC and mHLA-DR levels were dramatically reduced at the time of sepsis diagnosis when compared with healthy controls, whereas sPD-L1 concentrations were significantly elevated. There were no differences between RAP and CCI patients in ALC, sPD-L1, or mHLA-DR at the time of diagnosis or within 24 h after sepsis diagnosis. However, in contrast to the RAP group, CCI patients failed to exhibit any trend toward restoration of normal values of ALC, HLA-DR, and sPD-L1.
CONCLUSIONS: Septic patients demonstrate clinical and biological evidence to suggest they are immunosuppressed at the time of sepsis diagnosis. Those who develop CCI have a greater incidence of secondary infections and persistently aberrant markers of impaired host immunity, although measurements at the time of sepsis onset did not distinguish between subjects with RAP and CCI.
参考来源
- Stortz JA, Murphy TJ, Raymond SL, et al. Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis. Shock. 2018. PMID: 28885387. doi:10.1097/SHK.0000000000000981
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。